25,586 Shares of Johnson & Johnson $JNJ Purchased by N.F.U. MUTUAL UNIT MANAGERS Ltd

N.F.U. MUTUAL UNIT MANAGERS Ltd bought a new position in Johnson & Johnson (NYSE:JNJ – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,586 shares of the company’s stock, valued at approximately $6,778,000. Johnson & Johnson makes up about 1.2% of N.F.U. MUTUAL UNIT MANAGERS Ltd’s holdings, making the stock its 15th largest position.

Other institutional investors have also recently made changes to their positions in the company. CKW Financial Group raised its holdings in Johnson & Johnson by 0.9% in the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company’s stock worth $1,104,000 after acquiring an additional 37 shares during the last quarter. Silver Coast Investments LLC lifted its position in Johnson & Johnson by 3.8% in the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after acquiring an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV boosted its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after purchasing an additional 39 shares during the last quarter. Triumph Capital Management boosted its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock valued at $643,000 after purchasing an additional 39 shares during the last quarter. Finally, Kwmg LLC boosted its stake in Johnson & Johnson by 1.7% during the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock valued at $631,000 after purchasing an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Investors following JNJ have been watching these news items:

  • Positive Sentiment: Phase 4 results for TREMFYA in axial psoriatic arthritis met key endpoints, with significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation. The data could strengthen the drug’s commercial prospects. Article
  • Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
  • Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.3%

Shares of Johnson & Johnson stock opened at $270.54 on Friday. Johnson & Johnson has a twelve month low of $199.90 and a twelve month high of $290.25. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $267.53 and its 200 day moving average is $250.98. The company has a market cap of $651.27 billion, a price-to-earnings ratio of 40.99, a price-to-earnings-growth ratio of 2.72 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Morgan Stanley reduced their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a report on Thursday, October 15th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. TD Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Erste Group Bank downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Finally, UBS Group set a $270.00 price objective on Johnson & Johnson in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $276.54.

Get Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.